Dr Reddy’s semaglutide supply paused over API fault, shares dip 3.5%
Dr Reddy’s announced a pause in commercial supply of its generic semaglutide after uncovering an out‑of‑specification issue with the active pharmaceutical ingredient. The news knocked the stock about 3.5% and forces the company to cut its FY27 supply outlook, though it assures no impact on patient safety or existing regulatory filings.